INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer Ovarian cancer is the fifth leading cause of cancer death among women ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor …

A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today 48 presentations on Tumor Treating Fields …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step away from the healthcare industry and frequent international travel to spend more time with his family. “While this was a difficult decision, …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019, in New York City. Mr. Groenhuysen’s presentation will begin at 10:55 a.m. EDT. Mr. Groenhuysen will also participate in one-on-one meetings with investors throughout the day. A live …